IBS Is Associated with a High Financial Burden

DECEMBER 01, 2003

    Irritable bowel syndrome (IBS) is a common chronic and episodic gastrointestinal (GI) disorder that affects millions of Americans. In fact, IBS is more prevalent than hypertension, asthma, diabetes, and heart disease, and this disorder brings with it a comparable financial burden. The economic consequences of IBS to employers, however, were not investigated until recently.

    In a study published in the April 2003 issue of Archives of Internal Medicine, researchers determined the financial burden that IBS places on employers by examining direct and indirect costs of IBS for a national Fortune 100 manufacturer. Through retrospective analysis of administrative claims data, they found that employees with IBS incurred costs for employers that were on average 1.5 times higher ($6364 vs $4245; P < .001) than costs incurred by employees in the matched, control sample. Employees with IBS also used a significantly greater number of medical services (ie, physician visits and outpatient care) than did control employees.


Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 


Pharmacy Times Strategic Alliance

Pharmacist Education
Clinical features with downloadable PDFs

Next-Generation Pharmacist® Awards

3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference

Personalize the information you receive by selecting targeted content and special offers.